BETHPAGE, NY, September 30, 2010 (Press-News.org) With sales quota achievement at an all-time low and the worst economic downturn in memory, Find New Customers, a B2B sales and marketing automation consultancy, announces a series of webinars with top B2B marketing thought leaders. The "B2B Demand Generation Thought Leadership Series" is designed to help B2B companies develop the strategies and tactics necessary to increase sales-ready leads and close more business. The lineup of B2B marketing experts will be announced in early October. More information about the webinar series can be found at http://www.FindNewCustomers.com/B2B-webinar.
Paige O'Neill, VP of Corporate Marketing and Communications at Aprimo, says "We reached out to Find New Customers because of their remarkably broad and deep network of top marketing experts. Find New Customers is uniquely qualified to bring marketing professionals insightful thought leadership across several important marketing areas, including sales and demand generation."
Jeff Ogden, President of Find New Customers (http://www.findnewcustomers.com), says "With sales results slumping, it's clear business sellers are looking for fresh ideas and insights. This webinar series will connect them with top experts with those fresh idea and insights they so badly need.
Ogden, a sales and marketing expert, employs best practices in lead generation to help companies acquire customers and crush competitors via demand generation programs. His proven track record of exceeding targets speaks to his fearless competitor attitude and results-oriented nature. Jeff's recent works include popular white papers and eBooks including "How to Find New Customers", "Definitive Guide to Making Quote" and "Moving from Transactional to Conversational Email Marketing" (http://www.findnewcustomers.com/getcustomers).
About Find New Customers LLC
Find New Customers (http://www.findnewcustomers.com/) helps businesses implement demand generation programs and processes to grow revenue through quality sales leads. Company president, Jeff Ogden, is also the author of highly regarded white papers on topics such as demand generation, sales and email marketing. (www.findnewcustomers.com). In addition, he writes a popular blog, Fearless Competitor (www.fearlesscompetitor.net).
Find New Customers Announces Webinar Series on B2B Marketing and Demand Generation
Seven out of 10 companies say lack of quality sales leads is no. 1 problem; "B2B Demand Generation Thought Leadership Series" designed to teach companies how to increase sales-ready leads.
2010-09-30
ELSE PRESS RELEASES FROM THIS DATE:
Guide to Natural Eczema Treatments Hits the Market - From Eczema Free Forever TM
2010-09-30
Eczema Free Forever TM provides answers to practical, homemade and natural solutions, that the eczema suffering population in any part of the world can easily perform in the comfort of their home.
One in eight people suffer from eczema in the U.S. That's 15 million people. What causes eczema? Which eczema treatment works best? These are questions that the millions of people with the condition ask regularly.
There certainly is no shortage of medicines available on the market that lay claim to being the absolute best cure for eczema. The creams and oily goop that pass ...
Triple-negative breast cancers may have unique therapeutic target
2010-09-29
DENVER — Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Triple-negative breast cancers are breast cancers that have tested negative for estrogen receptors, progesterone receptors and HER2. Because of this biology, these cancers do not respond to endocrine therapies or trastuzumab.
"In other subsets of breast cancer, ...
Circulating tumor cells can provide 'real-time' information on patient's current disease state
2010-09-29
DENVER — Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
"The basic idea is that CTCs can provide real-time information about a patient's current disease state, acting as a 'liquid biopsy,'" said Siminder Kaur Atwal, Ph.D., senior research associate at Genentech. "They are much less invasive than tumor biopsies because they can be detected from a blood draw and ...
Biomarker panel identifies prostate cancer with 90 percent accuracy
2010-09-29
DENVER — Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.
The researchers, from Oxford Gene Technology (OGT) and its subsidiary, Sense Proteomic, Ltd., presented their findings at the Fourth AACR International Conference on Molecular ...
New biomarkers discovered for pancreatic cancer and mesothelioma
2010-09-29
DENVER — Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic and mesothelioma.
This technology would enable better clinical diagnosis at an earlier stage and may provide insight into new therapeutic targets, said Rachel Ostroff, Ph.D., clinical research director of Somalogic Inc.
"Currently these cancers are detected at an advanced stage, where the possibility of cure ...
African-Americans equally likely to benefit from erlotinib and other targeted lung cancer therapy
2010-09-29
DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
"This study has immediate implications for patient management. Patients with EGFR mutations have a much better prognosis and respond better to erlotinib than those who do not," said Ramsi Haddad, Ph.D., director of the Laboratory of Translational Oncogenomics at the Barbara Ann Karmanos Cancer Institute, and assistant ...
Novel biomarker may predict response to new VEGF receptor inhibitor
2010-09-29
DENVER — Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.
This is possible, the researchers from AVEO Pharmaceuticals, Inc. said, because they have used a new way of creating animal tumor models that mimic tumor variation seen in human. Based on the results of these studies, they have found a single biomarker that may predict resistance to tivozanib, an oral, triple VEGF (vascular endothelial growth factor) receptor inhibitor.
Tivozanib is in an ...
Nanotechnology brings personalized therapy 1 step closer to reality
2010-09-29
DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.
"We are making progress toward the goal of understanding how drugs work in different individuals," said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine. "Using new technologies makes it possible to measure effects of therapeutic agents in tumor cells and different cell populations within our patients. Now that we can make these measurements, we are one step closer to being able to ...
Method to detect bladder cancer earlier is under development
2010-09-29
DENVER — Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.
"Measuring expressions of microRNA in bodily fluid represents a very promising tool with widespread implications for screening," said Liana Adam, M.D., Ph.D., assistant professor in urology at The University of Texas MD Anderson Cancer Center.
Adam presented her findings at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic ...
c-Met may be a biomarker for metastatic hepatocellular carcinoma
2010-09-29
DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.
"Current therapies for HCC patients are 'one size fits all.' We propose ...
LAST 30 PRESS RELEASES:
With bird flu in raw milk, many in U.S. still do not know risks of consuming it
University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease
UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS
Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it
A closer look at biomolecular ‘silly putty’
Oxytocin system of breastfeeding affected in mothers with postnatal depression
Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles
Defensive firearm use is far less common than exposure to gun violence
Lifetime and past-year defensive gun use
Lifetime health effects and cost-effectiveness of tirzepatide and semaglutide in US adults
New members of the CDKL family of genes linked to neurodevelopmental disorders
Advancements in organ preservation: paving the way for better transplantation outcomes
Pitt study makes new insights into the origins of ovarian cancer
Topical steroid withdrawal diagnostic criteria defined by NIH researchers
CeSPIACE: A broad-spectrum peptide inhibitor against variable SARS-CoV-2 spikes
Understanding the origin of magnetic moment enhancement in novel alloys
BU researchers develop computational tools to safeguard privacy without degrading voice-based cognitive markers
Breakthrough in rapid polymer nanostructure production
Artificial photosynthesis: Researchers mimic plants
Social disadvantage can accelerate ageing and increase disease risk
Breaking free from dependence on rare resources! A domestic high-performance permanent magnet emerges!
Symptoms of long-COVID can last up to two years after infection with COVID-19
Violence is forcing women in Northern Ireland into homelessness, finds new report
Latin American intensivists denounce economic and cultural inequities in the global scientific publishing system
Older adults might be more resistant to bird flu infections than children, Penn research finds
Dramatic increase in research funding needed to counter productivity slowdown in farming
How chemistry and force etch mysterious spiral patterns on solid surfaces
Unraveling the mysteries of polycystic kidney disease
Mother’s high-fat diet can cause liver stress in fetus, study shows
Weighing in on a Mars water debate
[Press-News.org] Find New Customers Announces Webinar Series on B2B Marketing and Demand GenerationSeven out of 10 companies say lack of quality sales leads is no. 1 problem; "B2B Demand Generation Thought Leadership Series" designed to teach companies how to increase sales-ready leads.